Lyudmila G. Nikolaeva , Tatyana V. Maystat , Volodymyr S. Pylypchuk , Yuri L. Volyanskii and Galyna A. Kutsyna
Page: 8-12 | Received 21 Sep 2022, Published online: 21 Sep 2022
Full Text Reference XML File PDF File
The phase II, randomized, clinical trial was conducted in 40 HIV infected patients to evaluate the effect of oral immunomodulator Dzherelo on immune and viral parameters. The arm A (n = 20), received standard Anti-Retroviral Therapy (ART) consisting of zidovudine, lamivudine and efavirenz (AZT/3TC/EFV) and arm B (n = 20) received 50 drops of Dzherelo twice per day in addition to ART. After 2 months the total CD3 T-lymphocytes increased in ART recipients from 664 to 819 cells µL 1 (p = 0.06), whereas in Dzherelo recipients they rose from 595 to 785 cells µL 1 (p = 0.03). The population of CD4 T-cells expanded by 57.3% in ART (218-343; p = 0.002) and by 93.5% in Dzherelo arms (184-356; p = 0.004). The accrual in absolute and relative number of CD8+ lymphocytes in ART and Dzherelo recipients was 43.2% (2.7%) and 50.4% (-0.5%) , respectively. The CD4/CD8 ratio in Dzherelo recipients had increased from 1.495 to 1.940 (p = 0.03) but in the control group the increase was not significant, i.e., 1.418-1.613 (p = 0.14). About three-quarters (14/19) of patients on ART displayed the decrease in viral load (1718-1419 copies mL 1; p = 0.008), while 95% of patients on Dzherelo had a reduction in the number of viral copies (1793-1368 copies; p = 0.001). Dzherelo has a favorable effect on T-lymphocyte subsets and viral burden in HIV patients when given as an immunomodulating adjunct to ART.
Lyudmila G. Nikolaeva , Tatyana V. Maystat , Volodymyr S. Pylypchuk , Yuri L. Volyanskii and Galyna A. Kutsyna . Effect of Immunomodulator Dzherelo on CD4 + T-Lymphocyte Counts and Viral Load in HIV Infected Patients Receiving Anti-Retroviral Therapy.
DOI: https://doi.org/10.36478/rjpharm.2008.8.12
URL: https://www.makhillpublications.co/view-article/1815-9362/rjpharm.2008.8.12